Literature DB >> 10051299

Arterial flow conditions downregulate thrombomodulin on saphenous vein endothelium.

M Gosling1, J Golledge, R J Turner, J T Powell.   

Abstract

BACKGROUND: The antithrombogenic properties of venous endothelium may be attenuated when vein is implanted in the arterial circulation. Such changes may facilitate thrombosis, which is the final common pathway for saphenous vein arterial bypass graft occlusion. METHODS AND
RESULTS: Using human saphenous vein in a validated ex vivo flow circuit, we investigated (1) the possibility that arterial flow conditions (mean pressure, 100 mm Hg, 90 cpm, approximately 200 mL/min) alter the concentration of proteins involved in regulating thrombosis at the vessel wall and (2) the influence of ion channel blockade on such effects. Concentrations of thrombomodulin and tissue factor were quantified by Western blotting (ratio of von Willebrand factor staining) and immunohistochemistry (as a percentage of CD31-staining area). Thrombomodulin concentrations after 90 minutes of venous and arterial flow conditions were quantified by immunostaining (68.9+/-4.8% and 41.0+/-3.0% CD31, respectively; P<0.01) and by Western blotting (1.35+/-0.20 and 0. 15+/-0.03 ratio of von Willebrand factor, respectively; P<0.01). The ability of endothelial cells to generate activated protein C also decreased from 62+/-14 to 19+/-10 ng. min-1. 1000 cells-1 (P=0.01). The significant reduction in thrombomodulin was attenuated if calcium was removed from the perfusate but not by external vein stenting. Inclusion in the vein perfusate of drugs that reduce calcium entry (including Gd3+, to block stretch-activated ion channels, and nifedipine) abolished the reduction in thrombomodulin concentration observed after arterial flow conditions. In freshly excised vein, negligible concentrations of tissue factor were detected on the endothelium and concentrations did not increase after 90 minutes of arterial flow conditions, although the inclusion of nifedipine caused the immunostaining to increase from 3.0+/-0.4% to 8.5+/-0.7% CD31 (P<0.02).
CONCLUSIONS: In saphenous vein endothelium exposed to arterial flow conditions, there is rapid downregulation of thrombomodulin, sufficient to limit protein C activation, by a calcium-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051299     DOI: 10.1161/01.cir.99.8.1047

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  Gene therapy for the prevention of vein graft disease.

Authors:  Kevin W Southerland; Sarah B Frazier; Dawn E Bowles; Carmelo A Milano; Christopher D Kontos
Journal:  Transl Res       Date:  2012-12-27       Impact factor: 7.012

2.  Critical assessment of the outcome of infrainguinal vein bypass.

Authors:  J Golledge; J Iannos; J A Walsh; J R Burnett; R K Foreman
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

3.  Fluid shear stress alters the hemostatic properties of endothelial outgrowth cells.

Authors:  Ann E Ensley; Robert M Nerem; Deirdre E J Anderson; Stephen R Hanson; Monica T Hinds
Journal:  Tissue Eng Part A       Date:  2011-09-16       Impact factor: 3.845

Review 4.  Brothers and sisters: molecular insights into arterial-venous heterogeneity.

Authors:  Julius Aitsebaomo; Andrea L Portbury; Jonathan C Schisler; Cam Patterson
Journal:  Circ Res       Date:  2008-10-24       Impact factor: 17.367

5.  Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.

Authors:  Simone Mangan; Paula Clancy; Jonathan Golledge
Journal:  Thromb Res       Date:  2007-09-14       Impact factor: 3.944

6.  Endocardial Changes in Nonvalvular Atrial Fibrillation Without Atrial Thrombus-Thrombomodulin and Tissue Factor Pathway Inhibitor.

Authors:  Kang An; Ju Mei; Jiaquan Zhu; Min Tang
Journal:  Clin Appl Thromb Hemost       Date:  2018-01-24       Impact factor: 2.389

7.  Human saphenous vein organ culture under controlled hemodynamic conditions.

Authors:  Ayumi Aurea Miyakawa; Luis Alberto Oliveira Dallan; Silvia Lacchini; Thaiz Ferraz Borin; Jose Eduardo Krieger
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

Review 8.  Obstacles in haemocompatibility testing.

Authors:  W van Oeveren
Journal:  Scientifica (Cairo)       Date:  2013-05-07

Review 9.  Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects.

Authors:  Fiona A Martin; Ronan P Murphy; Philip M Cummins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-19       Impact factor: 4.733

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.